Hangzhou Tigermed Consulting Co., Ltd.
HNGZY · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $2 | $2 | $2 |
| % Growth | -85.3% | 7.8% | 1.9% | – |
| Cost of Goods Sold | $0 | $1 | $1 | $1 |
| Gross Profit | $0 | $1 | $0 | $0 |
| % Margin | 27.5% | 30.1% | 30% | 17.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | -$0 | $0 | -$0 |
| SG&A Expenses | $0 | -$0 | $0 | -$0 |
| Sales & Mktg Exp. | $0 | -$0 | $0 | -$0 |
| Other Operating Expenses | $0 | $0 | $0 | $1 |
| Operating Expenses | $0 | $0 | $0 | $1 |
| Operating Income | $0 | $0 | $0 | -$0 |
| % Margin | 9.5% | 17.8% | 9.2% | -27.4% |
| Other Income/Exp. Net | $0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | $0 | $0 | $0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | $0 | $0 | -$0 |
| % Margin | 35.9% | 12.9% | 10.6% | -26.6% |
| EPS | 0.1 | 0.25 | 0.19 | -0.47 |
| % Growth | -60% | 31.6% | 140.4% | – |
| EPS Diluted | 0.1 | 0.25 | 0.19 | -0.47 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | -$0 |
| % Margin | 44.7% | 18.4% | 12% | -18.8% |